| |
Top menopause center news stories... |
|
| |
|
|
| |
TZD Use Linked to Fracture Risk in Women 50 and Older |
|
| |
Patients with type 2 diabetes may face an increased fracture risk when treated with thiazolidinedione (TZD) drugs, data from a large observational study suggest. |
|
| |
|
|
| |
Estradiol Spray May Pose Risk for Kids and Pets |
|
| |
Menopausal women who use a spray form of topical estradiol (Evamist) to control hot flushes should avoid touching children and pets with treated areas of the skin, the FDA warned. |
|
| |
|
|
| |
Tapering Favored for Stopping Hormones After Menopause |
|
| |
For postmenopausal women who discontinue hormone therapy (HT), tapering treatment appears overwhelmingly favored over a sharp halt, researchers found. |
|
| |
|
|
| |
ENDO: Society Calls for New Look at Hormone Therapy |
|
| |
SAN DIEGO -- The risks and benefits of initiating postmenopausal hormone therapy may vary depending on the age of the patient and the length of time since menopause, according to a scientific statement released today by the Endocrine Society. |
|
| |
|
|
| |
FDA Approves Denosumab for Osteoporosis |
|
| |
WASHINGTON -- The FDA has approved denosumab (Prolia), a fully human monoclonal antibody, for treatment of postmenopausal women who have a high risk for osteoporotic fractures, including those with a history of fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapy. |
|
| |
|
|
![<!--[if gte mso 9]>
Normal
0
0
1
477
2720
22
5
3340
11.1282
<![endif]--><!--[if gte](/IMAGES/menopause-header.jpg "<!--[if gte mso 9]>
Normal
0
0
1
477
2720
22
5
3340
11.1282
<![endif]--><!--[if gte")
